Drug Discovery

Leap Therapeutics and BeiGene announce exclusive option and license agreement for DKN-01

Leap Therapeutics has announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand.

Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics

Acceleron Pharma has entered into a pulmonary research and discovery collaboration agreement with Fulcrum Therapeutics.

Achillion shareholders approve agreement to be acquired by Alexion

Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals.

Organovo and Tarveda Therapeutics announce definitive merger agreement

Organovo Holdings and Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction.

Charles River Laboratories to buy HemaCare for $380m

Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash.

3M to sell drug delivery business to Altaris Capital Partners in $650m deal

3M, a US-based manufacturing company, has agreed to sell almost all of its drug delivery business to an affiliate of Altaris Capital Partners for about $650m.

Retrogenix and Resonant Therapeutics announce strategic alliance to identify targets of anti-tumour antibodies

UK-based biotechnology company Retrogenix and US-based Resonant Therapeutics, Inc. announced today that they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.

Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline

Sanofi has agreed to acquire US-based clinical-stage biotechnology company Synthorx for about $2.5bn in an all-cash deal in a move to strengthen its immuno-oncology (IO) pipeline.

Incheon City envisions biotech Mecca by developing Songdo Global Biotech Cluster

The Incheon Metropolitan City government announced an ambitious plan for developing the Songdo Global Biotech Cluster in the Incheon Free Economic Zone.